CURANUM AG

EANS-Adhoc: CURANUM AG
Figures Q2-2009/ HY1 2009

@@start.t1@@--------------------------------------------------------------------------------   ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro   adhoc with the aim of a Europe-wide distribution. The issuer is solely   responsible for the content of this announcement. --------------------------------------------------------------------------------@@end@@

6-month report/Figures Q2-2009 / HY1 2009

13.08.2009

Ad hoc announcement

Second-quarter revenue within budget

CURANUM AG, Munich, achieved revenue of EUR 64.3 million in the second quarter of 2009. This represents an increase of 0.9% compared with the previous year's EUR 63.7 million. The revenue included income of EUR 0.5 million from our new senior citizens care facility of Scheffelhof in Bad Dürrheim. In addition, occupancy in May 2009 was slightly above the previous year levels. Revenue in the first half of 2008 totaled EUR 127.5 million, and consequently dipped slightly by 0.1% to EUR 127.4 million.

Despite the EUR 0.4 million rise in personnel costs, operating earnings before rental expenses (EBITDAR) were maintained at EUR 20.2 million in the second quarter of 2009 (previous year: EUR 20.2 million), which corresponds to an EBITDAR margin of 31.4%. Earnings before interest, tax, depreciation and amortization (EBITDA) fell from EUR 6.8 million in the previous year to EUR 6.2 million in the second quarter of 2009 as a result of further rental indexation adjustments. At EUR 2.4 million, depreciation and amortization in the current reporting period was identical to that of the previous year. Earnings before interest and tax (EBIT) fell from EUR 3.8 million (previous year: EUR 4.5 million) and earnings after tax reduced by EUR 0.6 million from EUR 1.7 million in the second quarter of 2008 to EUR 1.1 million in the second quarter of 2009. As a result, earnings per share (EPS) were down from EUR 0.05 to EUR 0.03 in the second quarter of 2009 compared to the previous year.

Compared with the first half of 2008, the net financial result improved by 8.3%, from minus EUR 4.8 million as of June 30, 2009 to minus EUR 4.4 million as of June 30, 2008. The after-tax result amounted to EUR 2.2 million (previous year: EUR 3.8 million), and earnings per share (EPS) totaled EUR 0.07, following EUR 0.12 in the previous year.

Cash flow from operating activities in the first half of the current financial year amounted to EUR 8.7 million, and, despite the lower operating result, was only slightly below cash flow in the comparable period of the previous year (EUR 9.0 million).

As a consequence of the dividend payment, the repurchases of own shares, and additions to earnings-neutral provisions for interest-rate hedging transactions, equity fell from EUR 64.1 million as of December 31, 2008 by a total of EUR 1.7 million to EUR 62.4 million at the end of the second quarter of 2009. Consequently, the equity ratio was 26.5% (previous year: 26.7%).

For the second half of 2009, we continue to anticipate a tough competitive environment, characterized by numerous new openings, restrictive care rate negotiations, and the continuation of difficult financing conditions. Due to the high supply of care facilities available for sale, accompanied by low level of purchasing demand, we expect that purchase prices will tend to fall. In view of this situation, we are highly confident that we will be able to exploit attractive opportunities.

Munich, August 13, 2009

The Management Board

@@start.t2@@|Key figures IFRS as of June 30, |              |              |              |              |
  |
|2009                                            |              |              |              |              |
  |
|                                    |            |              |              |              |              |
  |
|mil. EUR                          |Q2 -      |Q2 - 2008|HY 1/2009|HY 1/2008|Q1 - 2009|Q1 -
2008|
|                                    |2009      |              |              |              |              |
  |
|Sales                            |64.3      |63.7        |127.4      |127.5      |63.1        |63.7
  |
|EBITDAR                         |20.2      |20.2        |40.4        |41.9        |20.2        |21.7
  |
|EBITDA                          |6.2        |6.8         |12.6        |14.7        |6.4         |7.9
  |
|Depreciation                 |2.4        |2.4         |4.8         |4.7         |2.4         |2.3
  |
|EBIT                              |3.8        |4.5         |7.8         |10.0        |4.0         |5.5
  |
|Financial result          |-2.1      |-2.3        |-4.4        |-4.8        |-2.3        |-2.5
  |
|EBT                                |1.7        |2.2         |3.4         |5.3         |1.7         |3.0
  |
|Net profit                    |1.1        |1.7         |2.2         |3.8         |1.1         |2.1
  |
|                                    |            |              |              |              |              |
  |
|Cash Flow                      |6.1        |4.9         |8.7         |9.0         |2.6         |4.1
  |
|                                    |            |              |              |              |              |
  |

|                                                                                                 |
|                                                                                                 |@@end@@

@@start.t3@@end of announcement                                                 euro adhoc
--------------------------------------------------------------------------------@@end@@

ots Originaltext: Curanum AG
Im Internet recherchierbar: http://www.presseportal.ch

Further inquiry note:
Bettina Pöschl
Tel. +49(0)89-242065-69
E-Mail: bettina.poeschl@curanum.de

Branche: Healthcare Providers
ISIN:      DE0005240709
WKN:        524070
Index:    SDAX, CDAX, Classic All Share, Prime All Share
Börsen:  Frankfurt / regulated dealing/prime standard
              Berlin / free trade
              Hamburg / free trade
              Stuttgart / free trade
              Düsseldorf / free trade
              München / regulated dealing



Weitere Meldungen: CURANUM AG

Das könnte Sie auch interessieren: